𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sustained response to tumor necrosis factor α–blocking agents in two patients with SAPHO syndrome

✍ Scribed by Annette D. Wagner; Jan Andresen; Michael C. Jendro; Jan L. Hülsemann; Henning Zeidler

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
845 KB
Volume
46
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fcγ receptor type IIIA genotype and resp
Fcγ receptor type IIIA genotype and response to tumor necrosis factor α–blocking agents in patients with rheumatoid arthritis
✍ Alf Kastbom; Johan Bratt; Sofia Ernestam; Jon Lampa; Leonid Padyukov; Peter Söde 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

## Abstract ## Objective To determine whether a functional single‐nucleotide polymorphism in the gene encoding Fcγ receptor type IIIA (FcγRIIIA) correlates with the response to treatment with tumor necrosis factor α inhibitors in rheumatoid arthritis (RA). ## Methods The study population compris

Fcγ receptor type IIIA polymorphisms inf
Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α–blocking agents
✍ Zuhre Tutuncu; Arthur Kavanaugh; Nathan Zvaifler; Maripat Corr; Reena Deutsch; D 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

## Abstract ## Objective To determine whether polymorphisms in Fcγ receptor type IIIA (FcγRIIIA) correlate with clinical efficacy in patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) being treated with tumor necrosis factor α (TNFα) inhibitors. ## Methods The st

B cell depletion may be more effective t
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt

Outcomes after switching from one anti–t
Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
✍ Kimme L. Hyrich; Mark Lunt; Kath D. Watson; Deborah P. M. Symmons; Alan J. Silma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti‐TNF agent, although the benefits of switching are unknown. The pres